The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity
Tubman VN, Mejia P, Shmukler BE, Bei AK, Alper SL, Mitchell JR, Brugnara C, Duraisingh MT. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity. Antimicrobial Agents And Chemotherapy 2015, 60: 613-616. PMID: 26459896, PMCID: PMC4704178, DOI: 10.1128/aac.01668-15.Peer-Reviewed Original ResearchMeSH KeywordsAcetamidesAnimalsAntimalarialsBiological TransportErythrocytesHost-Parasite InteractionsHumansIntermediate-Conductance Calcium-Activated Potassium ChannelsMacaca mulattaMiceMice, Inbred C57BLPlasmodium falciparumPlasmodium knowlesiPlasmodium yoeliiTrityl CompoundsTrophozoitesWaterConceptsGardos channel inhibitorChannel inhibitorsSickle cell diseaseC57BL/6 miceClinical trialsCell diseaseAntimalarial developmentPlasmodium growthErythrocyte dehydrationGardos channelSenicapocBlood stagesBiochemical profileAntimalarial activityPrimate plasmodiaVitro growthInhibitorsPatientsParasitemiaBlockadeDiseaseMiceTrials